| Project/Area Number |
18K16813
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 56040:Obstetrics and gynecology-related
|
|---|
| Research Institution | Nihon University (2020)
Keio University (2018-2019) |
|---|
Principal Investigator |
KATOH Yuki 日本大学, 医学部, 助教 (60733649)
|
|---|
| Project Period (FY) |
2018-04-01 – 2021-03-31
|
| Project Status |
Completed (Fiscal Year 2020)
|
| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2020: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2019: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2018: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
|---|
| Keywords | ステムセルメモリーT細胞 / 免疫チェックポイント阻害薬 / 抗PD-1抗体療法 / 免疫チェックポイント阻害剤 / 免疫療法 / 子宮頸がん / 子宮頸癌 |
|---|
| Outline of Final Research Achievements |
Stem cell memory T (Tscm) cells are a novel subset of memory T cells. Compared with other memory T cells (e.g., central memory/ effector memory T cell), Tscm cells are less sensitive, long-lived, and proliferate quickly in response to antigenic stimulation to produce large numbers of effector T cells, which is expected to be applied to cancer immunotherapy. We investigated the mechanism of tumor antigen-specific CD8+ Tscm cells proliferation and the differentiation into effector T cells. Furthermore, we evaluated several candidates that might promote the proliferation of antigen-specific CD8+ Tscm cells, and found that these drugs enhanced the therapeutic effect of anti-PD-1 antibody in a tumor-bearing mouse model.
|
| Academic Significance and Societal Importance of the Research Achievements |
Tscm細胞の発生・増殖・分化のメカニズムは未だ不明な点が多いことから、本研究により得られた知見は、その理解に役立つものと考えている。さらに、抗PD-1抗体などの免疫チェックポイント阻害薬単独での奏効率は、効果を示すがん種においても20%程度であり、不応例に対する併用療法の開発が重要な課題となっているが、我々の同定した標的分子の阻害剤を併用することにより、より効果的な複合がん免疫療法の提供が可能となる。
|
